MDS vs AML Diagnosis in Genomic-Era Hematology

Distinguishing myelodysplastic syndromes (MDS) from acute myeloid leukemia (AML) increasingly requires multi-factor reasoning across blast percentages, genomic findings, cytogenetics, and treatment context.

Haem.io is designed to execute this diagnostic logic consistently while preserving traceability to specific criteria in WHO 2022 and ICC 2022 frameworks.

Why this matters

• Borderline presentations can alter treatment decisions and prognosis.
• Guideline complexity has grown beyond practical manual execution at scale.
• Auditable, deterministic tooling helps reduce inconsistency and drift.